Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCL70802 in CD70-positive Advanced Urological Neoplasms
NCT05990621Phase 1Recruiting
- Sponsor
- Changhai Hospital
- Start
- Jul 2023
- Primary completion
- Jan 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UCL70802 in renal cell carcinoma (RCC) and urothelial carcinoma (UC), sponsored by Changhai Hospital. Primary endpoints: Adverse Events at 2 years, Serious Adverse Events at 2 years and 2 more. Started Jul 2023; status: recruiting.
02
Drugs
UCL70802
03
Conditions
renal cell carcinoma (RCC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05990621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05990621.